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BACKGROUND: 
Two major factors for successful organ transplantation are better 
control of rejection and better prevention and treatment of infections. In 
renal allograft recipients, immunosuppressive drug therapy is the major 
cause of immunocompromised status and occurrence of infections, which 
arise most commonly as a result of invasion by endogenous opportunists. It 
may also follow colonization by exogenous environmental organisms and 
via transfer of cytomegalovirus along with the transplanted kidney. The 
overall incidence of opportunistic infections varies from center to center; up 
to 15% of renal transplant recipients die of these infections. Clinical signs 
and symptoms of infection in immunocompromised patients may be 
concealed or imitated by the underlying disease, and a high index of clinical 
suspicion is vital. The unusual pathogens encountered in these patients 
demand thorough investigation.  The success of management of 
opportunistic infections depends on strong clinical suspicion, early 
diagnosis, and prompt treatment. The challenges of early diagnosis of 
opportunistic infections and prompt treatment are great; the rewards are even 
greater.  
2 
 
Fungi are one of the important causes of opportunistic infection in 
renal transplant recipients. Invasive fungal infections are among the most 
important causes of mortality among transplant patients. The incidence of 
these infections is increasing due to greater number of transplant surgeries 
and usage of potent immunosuppression. Although fungal infections are less 
common among kidney transplant recipients (1- 14%), they are responsible 
for significant mortality in this group of patients. The occurrence of invasive 
fungal infections is highest in the early post transplant period, when 
immunosuppression is greatest. Prolonged antifungal therapy and surgical 
intervention are needed for control of fungal infections. Early and prompt 
diagnosis of the condition and intervention is required to prevent morbidity 
and mortality. 
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AIM  
 
 
To study the clinical profile, risk factors for acquiring fungal 
infections, its outcome and the factors influencing outcome in living and 
deceased donor renal transplant recipients. 
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REVIEW OF LITERATURE 
INTRODUCTION: 
         Despite technical, immunological, and therapeutic advances in the field 
of renal transplantation, infections remain a major barrier to a successful 
outcome. The high mortality associated with infections emphasizes the 
negative impact of immunosuppression on the recipient's immune system. 
More than 80% of renal transplant recipients suffer at least one episode of 
infection within 1 year of transplantation.
3
 
        Fungal infections after solid organ transplantation, despite a lower 
incidence than bacterial and viral infections, remain a major cause of 
morbidity and mortality. Fungal infections in different types of solid organ 
transplantation show various incidences, underlying pathogenesis, and 
modes of clinical presentation.
2
 As many as 14% of renal allograft 
recipients, 32% of heart recipients, 35% of heart-lung, 38% of pancreas 
recipients, and 42% of liver recipients have been reported to develop 
clinically significant fungal infections.
4
 Among fungi, the responsible 
pathogens include Cryptococcus neoformans, Aspergillus species, Candida 
species, Coccidioidomyces immitis, Histoplasma capsulatum, and 
Mucormycosis. 
5 
 
WHAT MAKES FUNGAL INFECTIONS SPECIAL? 
Fungi are eukaryotic organisms like humans. They have a more 
complicated genome and they synthesize proteins in a complex manner. 
Their replication process is also complex. And also fewer medications are 
available for their treatment. Even though they are less invasive, they are 
ubiquitous. Because of their complex structure, their eradication is difficult 
requiring long duration of medical therapy and surgical debridement. There 
is no vaccine available to prevent fungal infection.
6
  
The humans are protected from fungal invasion by Th1 helper cell 
response and macrophage activation. The human immune system mounts a 
type IV reaction against the fungal pathogen. The human body is not 
protected by Ab response. And antibody titre is not useful in diagnosis. But 
antigen detection is useful in diagnosis. 
RISK FACTORS FOR THE DEVELOPMENT OF FUNGAL INFECTION
6
 
• Anti Thymocyte Globulin (ATG) usage 
• Multiple anti rejection therapies 
• Neutropenia, antibiotics 
6 
 
• Cytomegalo virus (CMV), Hepatitis C Virus (HCV) and Epstein Bar 
Virus (EBV) infections 
• Graft dysfunction (serum creatinine > 2 mg/dl) 
Invasive fungal infection has a high mortality rate, because the infection 
is often advanced at the time of diagnosis and the disease is rapidly 
progressive. There is difficulty in establishing early diagnosis. The efficacy 
of therapeutic agents is limited by toxicity and drug interactions. 
TIME TABLE OF INFECTIONS IN RENAL TRANSPLANT 
RECIPIENTS
3
 
 
0–1 MONTH 
Bacterial: wound infection, pneumonia, urinary tract infection, 
pyelitis, bacteremia 
Viral: herpes simplex, hepatitis 
1–6 MONTHS 
Viral: CMV, Epstein–Barr, varicella zoster 
Fungal: Candida, Aspergillus and Cryptococcus 
Bacterial: Listeria, Legionella, Nocardia 
Protozoa: Pneumocystis carinii 
> 6 MONTHS 
Bacterial: community micro-organism, mycobacteria 
7 
 
Viral: hepatitis B or C, CMV chorioretinitis 
FUNGAL PATHOGENS ASSOCIATED WITH INFECTION
4
 
PREDOMINANT FUNGI 
Candida spp 
Aspergillus spp  
Cryptococcus neoformans 
EMERGING FUNGI 
Fusarium spp 
Trichosporon spp 
Malasezzia furfur 
Scedosporium spp 
Zygomycetes 
Dematiaceous moulds 
ENDEMIC FUNGI 
Histoplasma capsulatum 
Blastomyces dermatitidis 
Coccidioides immitis 
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SYSTEMIC FUNGAL INFECTIONS: COMPARATIVE DATA
1
 
 
 
 
 
 
 
INCIDENCE OF INVASIVE FUNGAL INFECTIONS
2
  
  
TRANSPLANT TYPE          INCIDENCE OF INFECTIONS (%) 
 Renal                                            1.4   -  14 
 Heart                                            5.0   -   21 
 Liver                                            7.0   -   42 
 Lung & Heart/Lung                    15.0   -   35 
 Pancreas                                     18.0   -   38 
 
 
 
 
 
Gallis et al  
(n-171) 
Nampoory et 
al (n-512) 
John et al 
(n-920) 
Jayakumar et 
al (n-362) 
PGI-CHD 
(n-850) 
Fungal  infection     
 
13% 3.7% 5.6% 19% 9.8% 
Candidiasis  2.3%  
 
1.6%  1.4%  13.8%  2.8% 
Cryptococcosis  5.8%  
 
0.5%  2.4%  0.8%  1.9% 
Aspergillosis  
 
1.2%  0.9%  1 %  3 %  2.3% 
Mucormycosis  1.2%  
 
0.4%  1.1%  1.5%  2.0% 
Others 
 
0.6%  -  0.9%  -  0.5% 
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PGI CHANDIGARH EXPERIENCE - 5 YEARS: 
9
 
 
                
                                              
Numbers of transplant 
follow  up patients 
245 
Invasive fungal infection 15 
 
Rhino cerebral 
Mucormycosis 
3(20.00%) 
Pulmonary 
Mucormycosis 
2(13.34%) 
Candida Septicemia 2(13.34%) 
Pulm. Aspergillus 2 (13.34%) 
 
Aspergillus wound 
infection 
2(13.34%) 
Aspergillus wound 
infection with graft 
invasion 
2 (13.34%) 
 
Ectopic Aspergillus 
abscess 
1 (6.67%) 
Disseminated 
Cryptococcus 
1 (6.67%) 
Pulmonary involvement 4(26.66%) 
Prevalence 6.12% 
10 
 
  MORTALITY RATES IN INVASIVE FUNGAL INFECTIONS
5
 
TRANSPLANT PATHOGEN MORTALITY (%) 
Kidney Candida spp 
 Aspergillus spp 
Cryptococcus neoformans 
23 – 71 
20 – 100 
0 -  6 
Liver Candida spp 
Aspergillus spp 
Cryptococcus neoformans 
6 – 77 
50 - 100     
0 – 22 
Lung or Heart/Lung Candida spp 
Aspergillus spp 
27 
21 – 100 
Heart Aspergillus spp 32 – 64 
Pancreas Candida spp 20 – 27 
 
AN OVERVIEW OF ANTIFUNGAL AGENTS  
AMPHOTERICIN B 
    Amphotericin B is the traditional drug of choice for most of the fungal 
infections. It is a rapidly effective fungicidal drug. It binds to ergosterol in 
fungal membrane and punches holes in the membrane leading to leakage of 
potassium and other intracellular molecules. It stimulates innate immune 
cells & also interacts with adaptive humoral immunity. It also increases 
levels of antibodies against fungal HSP90.
6
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     Acute infusion related toxicity correlates with increase in level of 
inflammatory cytokines. The most prominent disadvantage of amphotericin 
B is its nephrotoxic effect.
8
 The treatment of aspergillosis with amphotericin 
B in solid organ transplant recipients results in a higher incidence of 
nephrotoxicity because of the concomitant use of cyclosporine.
49
 Liposomal 
amphotericin B (AmBisome) has far fewer side-effects and can be much 
more safely used in patients with solid organ transplants, despite 
concomitant use of cyclosporine A. In a series of 187 transplant recipients, 
liposomal amphotericin B was discontinued due to side-effects in 3% of 
cases. The overall mean increase in serum creatinine levels was 20%. Other 
side-effects included low serum potassium concentrations (36%) and a rise 
in alkaline phosphatase levels (26%).
50
  
           Liposomal amphotericin B markedly decreases the death rate due to 
aspergillosis in neutropenic patients after bone marrow transplantation from 
90% down to 25% even when neutrophil counts are still low.
50
 The 
antifungal efficacy of AmBisome seems to be related to its ability to target 
fungi rather specifically.
51
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AZOLES: 
          Among azoles, fluconazole has been used effectively in localized 
Candida infections, and may also be an option in the treatment of systemic 
candidiasis,
52, 53
 but data supporting its use in pneumonia are lacking at the 
present time. Itraconazole or the new azole voriconazole
55
 are effective 
therapies against aspergillosis, candidiasis or cryptococcosis. They are well 
tolerated. Enzyme-inducing drugs such as rifampicin and phenytoin 
significantly reduce the oral bioavailability of Itraconazole, and plasma 
monitoring of its plasma concentration is recommended when enzyme-
inducing agents are co administered.
54
  
          Itraconazole has been shown to be as effective as amphotericin B in 
small series of neutropenic patients,
56, 55
 and in liver or heart transplant 
recipients.
56, 57
 Failure of Itraconazole treatment of pulmonary aspergillosis 
in heart transplant recipients has been reported, but most of these patients 
had been maintained on high-dose steroids.
59, 60
 
ECHINOCANDIN: 
 
          Caspofungin, Andidulafungin, Micafungin are all excellent 
fungicidals for Candidiasis and Candidemia including C. parapsilosis, krusei 
which may be resistant to azoles. Candins too have immuno-stimulatory 
13 
 
properties.
61
 They enhance fungal killing by neutrophils and macrophages 
which is done by unmasking β glucan. 
         Only IV formulations are available. No dose change is required for 
renal impairment. Caspofungin is approved for salvage treatment of invasive 
aspergillosis. It has got low toxicity profile which may include some LFT 
abnormalities. Secondary resistance is associated with point mutations in the 
Fks1 gene of β-D-glucan.
62
 There are recent reports of secondary resistance 
against candida and aspergillus species. 
 Modulation of immunosuppression has to be taken into account as a 
major component of fungal infection treatment. The use of hematological 
growth factors may prove to be useful in the near future in not only restoring 
the neutrophil count more quickly, but also increasing the capacity to 
contain fungal pathogens.
60
 
INDIVIDUAL FUNGAL INFECTIONS 
ASPERGILLUS INFECTIONS IN SOLID-ORGAN TRANSPLANT 
RECIPIENTS 
Lungs and sinuses are primary site of infection. Use of catheters may 
cause primary cutaneous infection. Dissemination to CNS and other organs 
is common. High mortality occurs especially in lung and liver recipients.
10
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PULMONARY INFECTION: 
             Airborne conidia (2.5-3 microns) are infective. Symptoms include 
fever, cough, dyspnea, pleuritic pain and hemoptysis, Necrotizing 
bronchopneumonia, single or multiple abscesses. Early diagnosis difficult. 
Radiographs often normal. Culture often negative. "Halo" sign on chest CT 
scan highly suggestive of Aspergillus. Definitive diagnosis is made from 
biopsy of lung tissue.
11
 
BLOOD VESSEL INVASION: 
 Invasion of blood vessel causes thrombosis, tissue infarction, 
hemorrhage and hematogenous dissemination.
13 
CNS INFECTION:  
         Presents either as manifestation of disseminated infection or as isolated 
CNS disease. Non-specific symptoms include fever, subtle change in level 
of consciousness. Also presents as abscess formation or less commonly 
meningitis.MRI lesions found at grey/white matter junction. Definitive 
diagnosis is by brain biopsy if no extraneural site more accessible.
14 
INVASIVE PULMONARY ASPERGILLOSIS: 
Classically, the major risk factors for invasive pulmonary aspergillosis 
include severe or prolonged neutropenia (absolute neutrophil count 
<500×10
6
·L
−1
) and prolonged high-dose corticosteroid therapy. 
21
 In the 
15 
 
absence of an effective host immune response, the spores mature into 
hyphae that can invade the pulmonary structures, particularly blood vessels. 
This results in pulmonary arterial thrombosis, hemorrhage, lung necrosis and 
systemic dissemination.
18
  
       Macrophages and granulocytes are the major immunoregulatory cells 
involved in host defenses against fungal infections. It has been demonstrated 
that corticosteroids suppress macrophage and granulocyte function, whereas 
little effect of the suppression of T‐lymphocyte function by cyclosporine has 
been noted. 
22
 
       The isolation of Aspergillus from bronchoalveolar lavage fluid and/or 
sputum has been shown to correlate with the histopathological changes of 
invasive pulmonary aspergillosis in bone marrow recipients
23
 in whom 
invasive forms cause the highest mortality.
19
 Aspergillus isolation from 
culture of respiratory secretions, pleural fluid or ascitic fluid has also been 
correlated with invasive Aspergillus infection and poor outcome in 
recipients of both liver and kidney transplants.
24 
In cases in which the 
diagnosis need to be proven, transbronchial biopsy is usually of little 
sensitivity, being as low as 20%, 
26
 whereas transthoracic needle biopsy or 
open lung biopsy provides a higher and more specific diagnostic yield.
27
  
16 
 
      Mortality rates from infections can be high (50–70%) and patient 
outcome depends on the early institution of antifungal therapy, the severity 
of the underlying disease and the speed of granulocyte recovery.
21, 28
  
          Invasive aspergillosis has been described as occurring following up to 
18% of heart and lung transplants,
 29
 but mortality can be reduced with pre-
emptive therapy and reduced immunosuppression.
12, 30
  
           Invasive pulmonary aspergillosis appears on radiographs as multiple 
ill-defined 1–2‐cm nodules that gradually coalesce into larger masses or 
areas of consolidation.
31
 An early computed tomography finding, but seen 
with thin collimation, is the rim of ground-glass opacity surrounding the 
nodules (computed tomography halo sign).
31
 This sign is, however, 
nonspecific and has also been described in patients with tuberculosis, 
mucormycosis and Wegener's granulomatosis.
7 
Cavitation is usually a late 
finding. The intracavitary mass composed of sloughed lung and the 
surrounding rim of air may be seen as “the air crescent sign”. Lobar 
consolidation is more common and less specific.
33
 Pleural effusion is 
unusual and adenopathy rare. 
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OTHER FORMS OF DISEASE RELATED TO ASPERGILLUS 
           Chronic necrotizing or semi-invasive aspergillosis typically occurs in 
patients with mild immunosuppression such as occurs in chronic obstructive 
pulmonary disease, sarcoidosis or underlying malignancy. It progresses 
slowly over a period of weeks or months. Aspergilli invade the tissues 
adjacent to cavities, increasing their size due to progressive necrosis. In 
transplantation, these slowly invasive forms are not described as distinct 
entities compared with the acute invasive forms.
25
  
            Allergic bronchopulmonary aspergillosis has occasionally been 
described after transplantation.
20
 Milder forms may have local consequences 
such as bronchocentric granulomatosis that may be underestimated. The 
physiopathology of allergic bronchopulmonary aspergillosis and 
bronchocentric granulomatosis may be better understood in the near future 
with the recent observation that aspergilli share epitopes similar to the 
cytoplasmic structures of epithelial cells. These local infections could trigger 
autoimmune processes.
36 
It is possible that such phenomenona do occur in 
the lungs of transplant recipients, leading to bronchial inflammation and 
stenosis.  
18 
 
          Aspergilloma can be present in pre-existing pulmonary cavities before 
transplantation. With immunosuppression, aspergilli can invade adjacent 
structures and lead to widespread disease.
29
 Preventive surgical removal of 
such mycetoma remains a matter of debate, especially for mycetoma 
resulting from previous invasive aspergillosis after bone marrow 
transplantation.
37
 
DIAGNOSIS:
 17
  
1. Radiology: chest X-ray and CT: halo sign 
2. Microbiology Respiratory secretions: BAL/biopsy - Direct microscopy 
and Culture. 
3. Serological surveillance: ELISA for galactomannan and Beta D glucan 
assay. 
4. Polymerase Chain Reaction. 
GALACTOMANNAN TEST - ASPERGILLUS ANTIGEN DETECTION
16
 
 It is an Immunoenzymatic sandwich enzyme immunosorbent assay 
(EIA). It uses a monoclonal antibody to GM polysaccharide antigen in 
fungal cell wall. Test duration is 3 hours. Specimen tested includes serum 
and tissue/fluid obtained from Broncho-alveolar lavage. Recommendation 
refers true positive only when more than one sample is positive. Positive 
19 
 
predictive value of the test is 71% and Negative predictive value is 88%. It 
has a Sensitivity of 50-94% and Specificity of 81-99%. False positive can 
occur with other fungi, translocation of gm antigen from food through 
damaged intestinal mucosa (e.g. Bread, cereal, rice, turkey) and mould-
derived antibiotics e.g. Penicillin. Use of β-D-glucan + GM ELISA in 
combination increases specificity & PPV. 
ASPERGILLUS PCR ASSAYS 
Detects 1-10 cfu/ml -Blood, BAL and Tissue not standardized. No 
commercial assays available. It has got variable sensitivity & specificity.  
For ‘in-house’ assays it has a sensitivity of 79-100% and specificity of 81-
100%.
56
Also antifungal treatment clears DNA from blood. 
BETA D GLUCAN ASSAY 
           It is a pan fungal assay. It has a good negative predictive value 100 
%. The test is positive in aspergillus, candida, fusarium, trichosporan, 
sachharomyces, and acremonium. Interestingly it is negative in Mucor. 
55
 
TREATMENT OF INVASIVE ASPERGILLUS INFECTION 
  Voriconazole is drug of choice. Liposomal amphotericin is second 
choice. Fluconazole is not useful. Itraconazole can be tried if disease is not 
very invasive. Posaconazole has also been reported to be efficacious. 
20 
 
Echinocandins are also useful. Surgical debridement is the final resort and 
had to be considered in appropriate cases.
41
 
VORICONAZOLE 
          It is given in a dose of 6 mg / kg IV for one day, followed by 4 mg / 
kg IV bd. Oral bioavailability is > 95 %. Oral dose is 400 mg bd, and then 
300 mg bd. Side effects include photopsia and LFT changes. In renal failure 
single dose IV is given followed by oral, because intravenous form has 
cyclodextrin which is retained in renal failure. Voriconazole has got several 
drug interactions. It is contraindicated with amphotericin. Rifampicin, eptoin 
and barbiturates reduce levels of voriconazole. QT prolongation can occur, 
hence drugs like cisapride etc., has to be avoided. Tacrolimus has to be 
reduced by one third and Cyclosporine has to be reduced by 50 %. Levels 
have to be monitored and dose has to be adjusted again after stopping 
voriconazole. 
42
  
AMPHOTERICIN 
       Amphotericin B is given in a dose of 1 to 1.5 mg/kg/day. Liposomal 
amphotericin B can be safely used up to a dose of 3 mg/kg/day. An 
intravitreal injection of amphotericin B (10mg) should be given for 
21 
 
endophthalmitis. Conventional amphotericin B should be avoided in renal 
failure.
43
 
ASPERGILLUS PREVENTION:
 40
 
Reduction of environmental risk factors 
– Gardening, Wood chips/mulch 
– Horse manure 
– Construction sites. 
CANDIDA INFECTIONS IN SOLID-ORGAN TRANSPLANT 
RECIPIENTS
47
 
It is the most common infection ranging from trivial to fatal. Serious 
infections are increasing. Highest risk of infection is in liver and pancreas 
recipients. Type and site of infection depends on species colonizing 
oropharynx and GI tract, use of invasive techniques and presence of drains 
and catheters. 
       Indwelling devices may result in Cystitis and retrograde infection of 
pancreatic graft / renal graft from bladder catheters can occur. Vaginal 
colonization also contributes to spread of infection. Colonization of GI Tract 
may result in hematogenous spread due to disruption of intestinal mucosa. 
Contamination of peritoneal cavity results in peritonitis. Biliary obstruction, 
22 
 
hepatic and splenic abscesses has also been reported. Hematogenous spread 
does occur from central venous catheters. 
CHANGING PROFILE OF CANDIDA INFECTION 
        Data from Sir Gangaram Hospital showed that Non albicans 
candidiasis constituted about 72%. 
Candida haemuloniiis an emerging pathogen constitutes about 10% of 
the non albicans species. This pathogen is resistant to Amphotericin B. 
Minimum Inhibitory Concentration of C lusitaniae, C guilliermondii and C 
parapsilosis was very high to Amphotericin B.
57
  
  Prevalence Data from Safdurjung Hospital (Sept 2003 –Nov 2004) - 
Of total 362 samples including 152 from blood, Candida was isolated in 
102 samples. 75.4% of the overall isolates were Candida non albicans. In 
Blood and other sterile sites Candida Non albicans were isolated in ~90% 
cases. Incidences of Amphotericin B resistance were as high as ~7%. This 
high resistance is attributable to a reduction in Membrane ergosterolin 
resistant mutants of some Candida spp.
58
         
Reports from Sanjay Gandhi Post-Graduate Institute of Medical 
Sciences revealed infection due to non-Candida albicans species is more 
23 
 
common than C. albicans. The incidence of Candida Non Albicans was 
67%. The mortality with Candidemia patients was 55% (SLIDE 6).
56
   
Reports from AIIMS Hospital in a 5 Year study (2001 -2005) revealed 
that the incidence of Non-albicans Candida was 79 -80%. C.tropicalis was 
the most commonly isolated pathogen –35.3%. High incidence of C. glabrata 
with 17.5% was seen. Anti-fungal resistance was found in 11.7%. Mortality 
in the first 4 years was high –72.2%, which was probably because of 
unawareness of disease prevalence.  
INVASIVE CANDIDA SPECIES IN SOLID ORGAN TRANSPLANTS:
 48
 
C. albicans (46%) 
C. glabrata (25%) 
C. krusei (3%) 
C. tropicalis (4%) 
C. parapsilosis (8%) 
C. Lusitania (1%), Multiple (11%), Other (2%). 
TREATMENT OF CANDIDA INFECTIONS 
 Indwelling venous catheters has to be removed. Eye examination has 
to be done to rule out endophthalmitis. Cultures and speciation has to be 
obtained as non-albicans strains are increasing.. Fluconazole is useful for 
C.albicans and all other species except C. glabrata or krusei. C. glabrata is 
24 
 
becoming increasingly resistant to Fluconazole.  Fluconazole has to be used 
with caution in critically ill patients. When Candidemia or invasive infection 
is present Caspofungin, Micafungin, and Anidulafungin are initially used 
until species available. These drugs should not be used with cyclosporine. 
Amphotericin B 0.5 - 0.7 mg/kg/day or Lipid formulation of Amphotericin B 
3 mg/kg/day is reserved for refractory disease.
39
 
CRYPTOCOCCOSIS  
         Cryptococcus (yeast) is causing human disease particularly in 
immunosuppressed. It has a worldwide distribution. 20% of non-HIV-
associated Cryptococcus infection occurs in solid organ transplant recipients. 
Infection is acquired through Pigeon droppings, soil, decaying wood chips 
etc.
32
 
PULMONARY INFECTION: 
         Primary infection occurs via inhalational route. Pulmonary infection 
may be asymptomatic (e.g., nodule) or it can also present as pneumonia. 
Chest radiograph shows nodules, infected lymph nodes, masses and 
consolidation. Cavitation, pleural effusion and adenopathy are less 
common.
32
 
 
 
25 
 
CNS INFECTION: 
        Hematogenous dissemination to CNS can occur resulting in meningitis 
and Cryptococcoma. Increased intracranial pressure (>200 mm H2O) is 
common and usually fatal. Symptoms include headache, fever, visual 
disturbances, nausea, vomiting, and cranial nerve abnormalities.
34
 May have 
subtle symptoms for months like altered personality, wide unsteady gait, low 
grade fevers. An India-ink smear of centrifuged spinal fluid sediment may 
reveal encapsulated yeasts in at least half of patients. Capsular antigen may 
be detected in cerebrospinal fluid by latex agglutination.CSF polysaccharide 
antigen is very reliable for diagnosis. Serum antigen test may be negative. 
MRI can rarely show Cryptococcoma.
35
 
TREATMENT 
PULMONARY INFECTION: 
200 - 400 mg/day fluconazole or Itraconazole (200mg BID) for 6 to 
12 months 
Severe infection: Amphotericin B 0.7 mg/kg/day ± 5-FC 
(100mg/kg/day) initially, then switch to oral fluconazole, 400 mg/day after 
clinically improved and continue for 6 to 12 months. 
Surgical resection may be needed for individuals with extensive lobar 
consolidation or large mass lesions.
34
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CNS INFECTION: 
Amphotericin B or lipid formulation + 5-FC for at least 2 weeks until 
CSF culture negative--need LP at 2 weeks. 
Consolidation of lung - with oral fluconazole 400 mg/day for 10 
weeks, then 200 mg/day for 6 to 12 months. Shunting or frequent LP’s may 
be needed for increased ICP. Large CNS lesions may require surgery.
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PREVENTION: 
Treat pretransplant cryptococcal infection aggressively. 
Screen high-risk donors, e.g. gardeners, pigeon breeders.  
MUCORMYCOSIS: 
It can be easily differentiated from Aspergillus by the following 
features. Mucor has an Aseptate hyphae, it branches at 90 degree angle and 
it is thicker (10 to 20 um).
38
  
CLINICAL PRESENTATION: 
Rhino cerebral involvement is the most common. It especially affects 
diabetics, though it can affect any immunosuppressed individual. Patient 
presents with fever, unilateral facial pain, nasal congestion, epistaxis, visual 
disturbance, proptosis, periorbital cellulitis, Cranial nerves II, III, IV, VI – 
ophthalmoplegia and black necrotic lesion in hard palate and nose.
39
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Patient can also present with pulmonary, cutaneous or gastro-intestinal 
involvement. Though disseminated mucormycosis is less common, it can 
also occur. 
Complications include Cranial Nerve dysfunction, Cavernous sinus and 
internal carotid artery thrombosis, cerebral abscess. Differential diagnosis 
includes Aspergillus, bacterial sinusitis and periorbital cellulitis.
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TREATMENT 
Surgical debridement is the most useful treatment modality and has to 
be resorted to it as early as possible. 
Medical management consists of Amphotericin B and caspofungin. 
Triazoles are not useful. Voriconazole treatment may predispose to 
mucormycosis. Echinocandins are not useful as a single agent. It has to be 
combined with Amphotericin B. 
PNEUMOCYSTIS JEROVECII 
          This is a frequent complication in transplant patients who do not 
receive prophylaxis with trimethoprim – sulfamethoxazole. The risk of PJP 
is increased in patients who have developed steroid-resistant rejection, CMV 
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infection, or other immunomodulating infections such as tuberculosis and 
hepatitis C.
56
  
        Transmission is usually person to person and air borne. The patient 
with P. jerovecii pneumonia usually presents with fever and dyspnea. 
Physical signs are often absent on examination. Some patients may show 
eosinophilia. Severe hypoxemia is usually present. Interstitial pneumonia is 
frequent, but X-radiographic abnormalities may be variable and not specific.  
DIAGNOSIS: 
       Chest X-Ray shows diffuse bilateral interstitial infiltrate or few 
infiltrates. CT scan shows ground glass opacities or cystic lesion (SLIDE 7). 
A correct diagnosis can be made only by BAL. Methanamine silver or 
toludine blue or cresyl violet and calcofluor are the stains that can be used. 
Direct FAT and PCR is available in few centers. Beta D glucan assay is also 
useful. 
TREATMENT: 
High-dose trimethoprim–sulfamethoxazole is the treatment of choice. 
The recommended dose is 15 mg/kg of trimethoprim, divided into 3–4 
doses. A treatment of 14 days is usually sufficient. In patients allergic to 
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sulfonamides, slow intravenous infusion of pentamidine, at doses ranging 
between 3 and 4 mg/kg per day according to the severity of the disease, may 
be indicated. Injection Pentamidine is nephrotoxic and also causes 
hypoglycemia, hypotension and pancreatitis. Alternative treatment includes 
clindamycin, 900 mg every 8 hours, plus primaquine, 15 mg by mouth, 
every day. 
X-RADIOLOGIC FINDINGS IN POST-TRANSPLANT PNEUMONIA 
Radiographic abnormality Acute development Chronic development  
Nodular infiltrate  Bacteria  Fungi, Nocardia, 
tuberculosis, pneumocystis 
jerovecii 
Cavitation  Bacteria (Legionella), 
fungi 
Tuberculosis  
Peri bronchovascular 
abnormality  
Bacteria, viruses 
(influenza) 
Fungi, CMV, Nocardia, 
tuberculosis, pneumocystis 
jerovecii 
Consolidation  Bacteria (Legionella) Fungi, viruses, Nocardia, 
tuberculosis, pneumocystis 
jerovecii 
Diffuse interstitial 
infiltrates  
 Fungi, CMV,  
pneumocystis jerovecii 
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COCCIDIOIDOMYCOSIS 
Coccidioides immitis is a soil saprophyte. Infection results from the 
inhalation of wind-borne spores arising from soil sites. In renal transplant 
recipients the infection may occur in endemic areas, and can present in the 
form of pneumonia or disseminated disease.
44
 
Pneumonia presents with non-specific symptoms such as fever, 
malaise, dry cough, headache, and dyspnea. Eosinophilia and erythematous 
skin lesions may be found in a few patients. X-radiologic findings show 
segmental pneumonitis, mild infiltrates, hilar adenopathy, and pleural 
effusion. Cavitation and solitary nodules (coccidioidoma) may develop in 
asymptomatic patients. The disseminated form is characterized by fulminant 
respiratory failure, disseminated intravascular coagulation and profound 
hypotension mimicking bacterial pneumonia and septic shock.  
TREATMENT: 
Caspofungin, amphotericin B, and azoles are usually effective.
71
 
RISING OPPORTUNISTIC FUNGAL INFECTIONS 
         T. glabrata is a yeast-like organism, normally present commensally in 
the human vagina. T. glabrata pneumonias have been reported in 
myelosuppressed patients with neoplastic disease. T. glabrata was isolated 
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from the bronchoalveolar lavage fluid of three of 26 of the present authors' 
lung transplant patients. Pneumonia can occur and progress despite 
amphotericin B treatment, but apparent lung infection has also been seen to 
regress without specific treatment, with bone marrow recovery after bone 
marrow transplantation.
44
  
       Invasive fungal infections caused by unfamiliar species are increasingly 
being reported in immunocompromised patients.
45
 These emerging 
opportunistic fungi include Fusarium, a common plant pathogen; Penicillium 
marneffei; Trichosporon beigelii; Blastoschizomyces capitatus and 
Malassezia furfur. Thus Fusarium can cause disseminated infection similar 
to aspergillosis in profoundly neutropenic patients.
46
  
        Invasive fungal infections pose a great challenge to transplant 
physicians, due to the lack of reliable diagnostic tests and limited therapeutic 
options. Invasive fungal infections are associated with a high overall 
mortality. Prompt diagnosis and treatment are necessary to avoid the life 
threatening complications and may greatly improve prognosis.  .  
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MATERIALS & METHODS 
Renal transplant recipients both cadaveric and living-related during 
the time period between august 2008 and May 2011 admitted with systemic 
fungal infections in nephrology ward were included in the study.  
Detailed history, duration of post transplant status, nature of 
immunosuppression, duration and type of symptoms, and history of other co 
morbid illnesses predisposing to fungal infections like Diabetes Mellitus and 
viral infections like HIV, HCV and CMV were taken. Data gathered 
included age, sex, date of transplantation, date of diagnosis, fungal pathogen, 
organs affected by infection, treatment and patient outcome. 
General examination and systemic examination followed by detailed 
examination of systems involved like eye, ENT, respiratory tract, GI tract 
etc. were done. 
Routine investigations like urinalysis & culture, complete hemogram, 
blood sugar, renal function tests, liver function tests, blood culture (bacterial 
& fungal), imaging of brain, Para nasal sinuses, thorax and abdomen ( like 
x-ray, USG, CT scan) were done. 
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Invasive investigations for tissue diagnosis and cultures like UGI 
scopy, bronchoscopy, nasal endoscopy and cystoscopy and tissue biopsy 
were done after obtaining written informed consent from the patient. 
Diagnosis was made by radiological findings, positive blood or 
bronchoalveolar lavage (BAL) cultures and tissue biopsies. For suspected 
cases of pulmonary involvement, fibreoptic bronchoscopy with 
bronchoalveolar lavage and transbronchial biopsy was performed. Materials 
from transbronchial biopsy were embedded in paraffin blocks, and sections 
of 5mm stained with hematoxylin-eosin. BAL fluids were cytocentrifuged 
and stained with Papanicolaou stain and Gomori methenamine silver stain. 
BAL fluids were also sent for bacterial, fungal, viral and mycobacterial 
cultures.  
Specimens for fungal isolation are plated on inhibitory mold media, 
brain-heart infusion agar, and mycobiotic agar (Gibco Diagnostics, Madison, 
Wisc.). Some fungi (Histoplasma capsulatum) can take up to 25 days to 
grow. Fungal cultures were incubated at 30
.
C for atleast 4 weeks. Plates 
were evaluated daily for the first 7 days and at least twice per week 
thereafter. 
 Diagnosis of invasive fungal infections was made in the presence of 
at least one of the following criteria: 1) histopathological evidence of tissue 
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invasion on biopsy specimen; 2) positive culture from deep tissue specimen 
such as blood, cerebrospinal fluid (CSF), peritoneal fluid; 3) KOH mount of 
specimen showing pseudohyphae and/or budding yeast. For diagnosis of 
Cryptococcus, India ink preparation of the sample (CSF) was done.  
In this study esophageal candidiasis was included as systemic fungal 
infection. It was diagnosed by upper GI scopy and histopathological 
examination of mucosal biopsy. 
All the patients were treated with intravenous Amphotericin B with a 
maximum cumulative dose of 1.5 to 2 gms. Those who had sinusitis due to 
mucormycosis underwent sinus surgery. Esophageal candidiasis was also 
treated with intravenous Amphotericin B till a cumulative dose of 500mg 
followed by repeat upper GI scopy. If esophageal candidiasis was persistent, 
another 500mg of intravenous Amphotericin B was given.  
In the above patients, etiology, clinical profile, risk factors, prognostic 
indicators and outcome were analyzed with appropriate statistical analysis. 
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STATISTICAL METHODS 
Microsoft excel 2007 was used to calculate mean. 
Binomial test was used to analyze factors predisposing the occurrence of 
fungal infections. 
Student t test was used for analyzing the factors influencing patient outcome. 
Differences were considered to be significant if the p-value was less than 
0.05. 
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RESULTS 
This study was conducted between Aug’ 08 and April’ 11, in the 
department of nephrology, government general hospital, chennai. Twenty 
two patients were diagnosed with systemic fungal infections during this 
period. The mean age of the study patients was 35.55 yrs. The male to 
female ratio was 1.75:1.  
The mean duration of disease before renal transplant for these patients 
was 16.5 yrs. And the mean dialysis duration was 7.8 yrs. 
TABLE 1: PRETRANSPLANT COMORBIDITIES IN PATIENTS WITH 
FUNGAL INFECTIONS 
Co morbidity  Number Percentage  
Diabetes mellitus 1 4.5 
Systemic Lupus Erythematosus (SLE) 1 4.5 
Liver disease 0 0 
Human Immunodeficiency Virus (HIV) 0 0 
Hepatitis B Virus (HBV) 1 4.5 
Hepatitis C Virus (HCV) 1 4.5 
Cytomegalo Virus (CMV) 0 0 
Pulmonary Tuberculosis (TB) 2 9 
Fungal infection 2 9 
No comorbidities  14 64 
Total  22 100 
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No significant comorbidity was observed in 64% of the study population. 
TABLE 2: TYPE OF RENAL DONATION IN THE STUDY POPULATION 
Type of transplant Living donor Deceased donor Total  
Number of infections 17 5 22 
Percentage  77.5 22.5 100 
 
77.5% of infections were noticed in living donor renal transplant 
recipients compared to deceased donor renal transplant recipients (22.5%). 
TABLE 3: TYPE OF IMMUNOSUPPRESSION AND NUMBER OF FUNGAL 
INFECTIONS 
Type of 
immunosuppression 
CsA+AZA+PDN CsA+MMF+PDN TAC+MMF+PDN Total  
Number of 
infections 
8 5 9 22 
Percentage  36 23 41 100 
 
Among the twenty two patients with fungal infections, 41% received 
tacrolimus (TAC), mycophenolate (MMF) and Prednisolone (PDN). Thirty 
six percent received cyclosporine (CsA), azathioprine (AZA) and 
Prednisolone. The rest received cyclosporine, mycophenolate and 
Prednisolone. 
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TABLE 4: TIME OF ONSET OF GRAFT DYSFUNCTION (GDF) AND 
NUMBER OF INFECTIONS 
Time of onset of 
GDF 
0 – 3 m 4 – 12 m 13 – 24 m No GDF Total  
Number of 
infections 
12 4 4 2 22 
Percentage  55 18 18 9 100 
  
The average time to onset of GDF was 7.1 months. Fifty five percent 
of patients with fungal infections developed GDF with in 3 months. Seventy 
three percent of infections occurred within a year. 
TABLE 5: TIME OF PRESENTATION OF FUNGAL INFECTIONS AFTER 
TRANSPLANTATION 
Time of presentation 0 – 6 months 7 – 12 months > 13 months  
Number of infections 12 2 8 
Percentage  55 9 36 
Mean  12 
Range  0.5 – 83 months 
 
Fifty five percent of patients developed fungal infections within 6 
months. The mean time of presentation is 12 months (range 0.5 – 83 
months). 
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TABLE 6: FACTORS PREDISPOSING THE OCCURRENCE OF FUNGAL 
INFECTIONS 
Factors  Present  Absent  Percentage  P-value 
GDF 20 2 91 0.000 
Surgical procedure 3 19 14 0.001 
Post Transplant DM 6 16 27 0.052 
HBV 2 20 9 0.000 
HCV 3 19 14 0.001 
CMV 11 11 50 1.000 
Bacterial infections 12 10 55 0.832 
Anti Rejection Therapy 8 14 36 0.286 
Leucopenia  11 11 50 1.000 
Anemia  (<11g/dl) 9 13 41 0.523 
Thrombocytopenia 9 13 41 0.523 
 
Binomial test has been used for analyzing the above table (p-value < 
0.05 is significant) 
Graft dysfunction alone seemed to be a risk factor for the occurrence 
of fungal infection. Though many patients received anti rejection therapy 
(ART, 36%) and cytomegalovirus (CMV, 50%) and bacterial infections 
(55%), leucopenia (55%), anemia (41%) and thrombocytopenia (41%) were 
present in many patients, they did not predispose to the occurrence of fungal 
infections. (No statistical significance). 
40 
 
TABLE 7:  FUNGAL INFECTIONS AND SITE OF OCCURRENCE 
Site of fungal infection Number  Percentage 
Gastro intestinal tract 6 22 
Lung 6 22 
Upper  respiratory tract 4 15 
Urinary tract 6 22 
Blood stream 3 11 
Central nervous system 2 8 
 
Fungal infections commonly occurred in gastrointestinal tract (GIT), 
lung and urinary tract, each 22%. Other sites were upper respiratory tract 
(15%), blood stream (11%) and central nervous system (CNS, 8%). 
TABLE 8: TYPES OF RENAL HISTOPATHOLOGY 
Histopathology 
 
Number  Percentage 
Acute cellular rejection 7 29 
Chronic humoral rejection  2 8 
Chronic allograft nephropathy 3 13 
Acute tubular necrosis 4 17 
Pyelonephritis  1 4 
Not biopsied 7 29 
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Fifteen of the twenty two patients underwent renal biopsy. Acute 
cellular rejection (29%) was the commonest histopathology followed by 
acute tubular necrosis. 
TABLE 9:  
Organism  Number  Percentage 
Candida species 14 62 
Aspergillus  3 13 
Mucor  4 17 
Cryptococcus  1 4 
Pneumocystis  1 4 
TYPE OF FUNGAL PATHOGEN CAUSING INFECTION 
Candida species (62%) is the commonest organism causing fungal 
infection. The other common organisms are Mucor (17%) and Aspergillus 
(13%).  
TABLE 10: GRAFT AND PATIENT OUTCOME OF PATIENTS WITH 
FUNGAL INFECTIONS 
Outcome  Number  Percentage 
Normal graft function 6 27 
Stable graft dysfunction 7 32 
Graft loss 9 41 
Survived  11 50 
Expired  11 50 
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TABLE 11: FACTORS INFLUENCING PATIENT OUTCOME 
Parameter  Survived  Expired  P-Value 
Deceased donor 4 1 
0.000* 
Living donor 7 10 
TMP 4 5 0.682 
CAP 4 4 1 
CMP 3 2 0.631 
DGF 4 3 0.666 
ART 4 2 0.362 
PTDM 4 2 0.362 
HBV 1 1 1 
HCV 2 1 0.557 
CMV 5 6 0.687 
Bacterial infection 7 5 0.416 
Thrombocytopenia  3 6 0.211 
Leucopenia  2 9 0.001* 
Anemia  6 6 1 
Alb < 3.5gm/dl 3 10 0.001* 
GDF 9 11 0.152 
Candida 7 7 1 
Pneumocystis  1 0 - 
Mucor  1 3 0.291 
Aspergillus  2 1 0.557 
Cryptococcus  0 1 - 
Graft loss 3 6 0.211 
Normal graft function 4 2 0.362 
Stable graft dysfunction 4 3 0.666 
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Student t test was used for analyzing the above data. p-value < 0.05 
was considered as significant. 
Fifty percent of patients with fungal infections expired. Graft loss 
occurred in 41% of patients. Thirty two percent of patients continued to have 
stable graft dysfunction. 
Leucopenia and thrombocytopenia influenced patient outcome by 
contributing to mortality (p value - 0.001). And also more significant 
number of deaths occurred in patients who received renal allografts from 
living donor (p value - 0.001). 
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DISCUSSION 
This study was conducted in the Department of Nephrology, 
Government General Hospital, chennai during the period between Aug’ 08 
and April’ 11. Twenty two patients were diagnosed with systemic fungal 
infections during this period.  
The mean age of the study patients was 35.55 yrs.  
The male to female ratio was 1.75:1.  
In a 10 year study done in Iran (from 1998 to 2008), the mean age of 
patients was 49 yrs and the male to female ratio was 4.2:1.
65
  In a study by 
Chugh et al, all patients were males with a mean age of 31.05 ±7.73 years 
(range 21-42 years). 
66
 
In the present study, living donor renal transplant recipients acquired 
77.5% of infections compared to deceased donor recipients (22.5%). 
  In the present study, Fifty five percent of fungal infections occurred 
with in 6 months of renal transplantation. Sixty four percent of infections 
occurred within a year.  
According to Abbott et al, majority of the fungal infections occurred 
within 6 months
67
. In a study by Chugh et al, infection occurred within the 
first year following transplantation in seven patients and after the first year 
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in the others.
66
 In a 10 year study done in Iran (from 1998 to 2008), 74% of 
invasive fungal infections occurred with in 1 yr. In another retrospective 
study (from 1987 to 1997) done in our department, out of 66 episodes of 
fungal infection 4 episodes occurred within 1 month; 28 between 1 and 6 
months; and 37 after 6 months i.e., nearly 50% of the infections occurred 
within 6 months.
68
 This phenomenon may be because of the use of numerous 
and higher doses of immunosuppressive agents. 
In the present study, Candida species (62%) is the commonest 
organism causing fungal infection. The other common organisms are Mucor 
(17%) and Aspergillus (13%). Cryptococcus and pneumocystis constituted 
4% each.  
In a retrospective study done in our department, Candida was the 
commonest pathogen, causing 50 of the fungal infection episodes (72.5%). 
Aspergillus (11 episodes, 16%), Cryptococcus (3 episodes, 4.3%), 
Pneumocystis (3 episodes, 4.3%), and Mucormycosis (2 episodes, 2.8%) 
constituted the rest.
68
  In the Iranian study, mucormycosis (11/21) was the 
commonest infection followed by Candidiasis (4/21) and Aspergillus 
(3/21).
65 
In a study by fishman et al., candida and Aspergillus were the 
common organisms.
69 
Infection with Cryptococcus neoformans was 
observed in eight patients (42%), Candida albicans in seven (37%), Mucor 
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species in two (11%), Aspergillus flavus in one (5.5%), and a mixed 
infection with Aspergillus and Cryptococcus in one patient (5.5%). 
In the present study, fungal infections commonly occurred in 
gastrointestinal tract (GIT), lung and urinary tract, each 22%. Other sites 
were upper respiratory tract (15%), blood stream (11%) and central nervous 
system (CNS, 8%). In a retrospective study done in our department, sites of 
infections were GI tract (35, 50.7%), respiratory tract (18, 26%), urinary 
tract (8, 11.5%), CNS (3, 4.3%), and graft (2, 2.8%).The sites of infection 
were almost similar to that in the present study.
68
  
In the literature, the risk factors for developing fungal infection in the 
post renal transplant setting were the following like deceased donor and 
retransplantation, older age, high doses of immunosuppression for anti 
rejection treatment, diabetes mellitus, CMV infection, bacterial infection 
with prolonged antimicrobial therapy, surgical interventions, indwelling 
catheters and anatomical abnormalities of the urinary tract.
70
 
 In the present study, graft dysfunction alone seemed to be a risk 
factor for the occurrence of fungal infection. Though many patients received 
anti rejection therapy (ART, 36%) and cytomegalovirus (CMV, 50%) and 
bacterial infections (55%), leucopenia (55%), anemia (41%) and 
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thrombocytopenia (41%) were present in many patients, they did not 
predispose to the occurrence of fungal infections. (No statistical 
significance).  
In a retrospective study done in our department, predisposing factors 
were anti-rejection therapy in 24 cases, bacterial infections in 19, leukopenia 
in 12, tuberculosis in 7, and CMV infection in 5.
68 
This difference may be 
due to the small number of patients in the present study. In a study by Chugh 
et al, graft function was normal at the time of diagnosis in 13 patients (68%) 
while it was impaired (serum creatinine 160umol/l) in six patients (32%). 
66
 
In the retrospective study done in our department, Six out of 10 
diabetic recipients developed fungal infections.
68
 But in the present study, 
only one patient had pre transplant diabetes mellitus. He developed fungal 
infection in the post transplant period. In a study by Chugh et al, apart from 
immunosuppressive drugs, predisposing factors included post-transplant 
diabetes mellitus in two and leukopenia in two patients.  Concomitant 
bacterial infections were present in seven patients
66
. 
In the present study 50% (11/22) of patients with fungal infection 
died. In the retrospective study done in our department, a total of 36 out of 
60 patients with fungal infection died (mortality 60%). 
68  
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In the present study, high percentage of deaths occurred in patients 
with mucormycosis (75%, 3 of 4); all of them had rhino cerebral Mucor with 
GDF, post transplant diabetes mellitus and leucopenia.  50% of patients with 
candida infections died. Three had blood stream and urinary tract infections, 
the remaining 4 deaths were due to candida UTI and bacterial sepsis. All 
those patients who had candida esophagitis survived.  Thirty three percent of 
patients with Aspergillus (1 out of 3) and 100% of cryptococcal meningitis 
patients died (one patient). 
In the Iranian study, 52.4% (11/21) of patients died due to fungal 
infection, mostly due to Mucormycosis (74%) 
65
.  
Leucopenia (9/11, 82%) and thrombocytopenia (6/9, 66%) influenced 
patient outcome by contributing to mortality. And also more significant 
number of deaths occurred in patients who received renal allografts from 
living donor (10 out of 17, 59%). Their association was statistically 
significant. 
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CONCLUSIONS 
 
 
1. Candida species was the commonest fungal pathogen causing 
infection in the renal transplant recipients (62%). 
2. Gastrointestinal, lung and urinary tracts were the common sites of 
fungal infection (22% each). 
3. Majority of fungal infections occurred in the first year (64%). 
4. Graft dysfunction predisposed to the occurrence of fungal infections. 
5. The mortality rate was 50%. 
6. Leucopenia (82%) and thrombocytopenia (66%) were associated with 
high mortality. 
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